In This Article:
It is usually uneventful when a single insider buys stock. However, When quite a few insiders buy shares, as it happened in AN2 Therapeutics, Inc.'s (NASDAQ:ANTX) case, it's fantastic news for shareholders.
While we would never suggest that investors should base their decisions solely on what the directors of a company have been doing, we would consider it foolish to ignore insider transactions altogether.
View our latest analysis for AN2 Therapeutics
AN2 Therapeutics Insider Transactions Over The Last Year
The Independent Director Robin Readnour made the biggest insider purchase in the last 12 months. That single transaction was for US$213k worth of shares at a price of US$1.16 each. That means that an insider was happy to buy shares at around the current price of US$1.27. That means they have been optimistic about the company in the past, though they may have changed their mind. While we always like to see insider buying, it's less meaningful if the purchases were made at much lower prices, as the opportunity they saw may have passed. Happily, the AN2 Therapeutics insiders decided to buy shares at close to current prices.
In the last twelve months insiders purchased 277.00k shares for US$291k. But they sold 17.61k shares for US$24k. Overall, AN2 Therapeutics insiders were net buyers during the last year. The chart below shows insider transactions (by companies and individuals) over the last year. By clicking on the graph below, you can see the precise details of each insider transaction!
There are always plenty of stocks that insiders are buying. If investing in lesser known companies is your style, you could take a look at this free list of companies. (Hint: insiders have been buying them).
Insiders At AN2 Therapeutics Have Bought Stock Recently
There has been significantly more insider buying, than selling, at AN2 Therapeutics, over the last three months. In fact, three insiders bought US$291k worth of shares. On the other hand, insiders netted US$24k by selling. Insiders have spent more buying shares than they have selling, so on balance we think they are are probably optimistic.
Does AN2 Therapeutics Boast High Insider Ownership?
Looking at the total insider shareholdings in a company can help to inform your view of whether they are well aligned with common shareholders. A high insider ownership often makes company leadership more mindful of shareholder interests. From our data, it seems that AN2 Therapeutics insiders own 6.5% of the company, worth about US$2.5m. We do generally prefer see higher levels of insider ownership.